Notice of NIDA's participation in PAR-18-694 "Interdisciplinary Research Teams to Investigate Reciprocal Basic Behavioral and Social Linkages Between Sleep and Stress (R24 - Clinical Trial Optional)"

Notice Number: NOT-DA-18-007

Key Dates
Release Date: March 13, 2018

Related Announcements

Issued by
National Institute on Drug Abuse (NIDA)


The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA)is participating in PAR-18-694, "Interdisciplinary Research Teams to Investigate Reciprocal Basic Behavioral and Social Linkages Between Sleep and Stress (R24 - Clinical Trial Optional)."
The following changes have been made to reflect NIDA's participation in this FOA:
Part 1. Overview Information
Components of Participating Organizations
Division of Program Coordination, Planning, and Strategic Initiatives, Office of Behavioral and Social Sciences Research (OBSSR)
All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. OBSSR may co-fund applications assigned to those Institutes/Centers.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s) 

93.273; 93.846, 93.279
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
The text that follows this sentence is hereby to be considered as information inserted at the end of the original Funding Opportunity Description in Part 2, Section I, of PAR-18-694.
In addition to research areas already listed in the Funding Opportunity Description, NIDA is interested in applications that address important gaps in this area, described as follows:
Addiction, drug-taking, withdrawal, and relapse all interactively affect stress and sleep and circadian patterns which, in turn affect the neural circuitry subserving reward evaluation, decision-making, and impulsive behavior.  In complement, individuals take drugs in response to stressors which affect sleep or they take drugs because of sleep disturbances and sleep deprivation which affect stress.  Sleep disturbance and stress are affected not only by day-to-day interactions with personal and community environments, but also by the neurophysiological make-up of the individual.  That is, the same environmental stressors and personal interactions will affect individuals differently depending on neurobiological and genetic factors; sex differences included. To completely understand substance use disorders and treatment, the interactions of these factors need to be considered together by multidisciplinary teams.  The National Institute on Drug Abuse (NIDA) is interested in supporting a multidisciplinary team to assess and study the effect of multiple factors that can lead to prevention and treatment of affected individuals. The investigative team should be interdisciplinary with a clear behavioral focus and can also include but not be limited to, the following areas of expertise: behavioral and cognitive sciences, childhood and adolescent development, epidemiology, genetics and epigenetics, cellular and molecular neurobiology, neurophysiology, brain imaging, neuroendocrinology, and sleep medicine.  Emerging technologies (such as Ecological Momentary Assessment, wearable physiological monitors, etc.) can be leveraged to understand individual differences in levels of stress and sleep quality and how these interact with each other to affect drug-taking, withdrawal symptoms, predictions of relapse, and recovery.
Examples of studies focusing on stress and sleep and their relationship to drug abuse and addiction in animal models or clinical research:

  • Examining environmental factors and personal relationships that contribute to stress reactivity and sleep disturbances as risk factors for drug abuse.
  • Assessing the trajectory of repeated exposure to adverse environmental conditions (including physical or sexual abuse) to development of coping behavior and sleep quality leading to drug abuse.
  • Determining how stress reactivity and sleep disruption affect neural circuitry involved with decision-making or with reward processing.
  • Assessing the interaction of stress and sleep disruption/deprivation in different developmental stages from childhood to adolescence to adulthood.
  • Assessing sex differences in reaction to stress and sleep disturbance as risk factors for substance use disorders
  • Determining mediating roles of stress and sleep on drug use.
  • Developing and testing novel interventions that integrate putative behavioral targets that converge on stress and sleep endpoints.
  • Studying brain structures (e.g., habenula) or networks (e.g., hypocretin/orexin) that are involved in stress behavior, sleep and circadian cycles, and reward.
  • Focusing on inflammation as caused or exacerbated by environmental stress, sleep disturbances and its relation to drug abuse.
  • Determining the consequences of drug use and stress on changes in the lymphatic system.
Section VII. Agency Contacts
The following contacts have been added:
Scientific/Research Contact(s)
Harold Gordon, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Financial/Grants Management Contact(s)
Ericka Wells
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-6705

All other aspects of this FOA remain unchanged.


Please direct all inquiries to:

Harold Gordon, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504